Abstract
Smallpox vaccine based on live, replicating vaccinia virus (VACV) is associated with several potentially serious and deadly complications. Consequently, a new generation of vaccine based on non-replicating Modified vaccinia virus Ankara (MVA) has been under clinical development. MVA seems to induce good immune responses in blood tests, but it is impossible to test its efficacy in vivo in human. One of the serious complications of the replicating vaccine is eczema vaccinatum (EV) occurring in individuals with atopic dermatitis (AD), thus excluding them from all preventive vaccination schemes. In this study, we first characterized and compared development of eczema vaccinatum in different mouse strains. Nc/Nga, Balb/c and C57Bl/6J mice were epicutaneously sensitized with ovalbumin (OVA) or saline control to induce signs of atopic dermatitis and subsequently trans-dermally (t.d.) immunized with VACV strain Western Reserve (WR). Large primary lesions occurred in both mock- and OVA-sensitized Nc/Nga mice, while they remained small in Balb/c and C57Bl/6J mice. Satellite lesions developed in both mock- and OVA-sensitized Nc/Nga and in OVA-sensitized Balb/c mice with the rate 40–50%. Presence of mastocytes and eosinophils was the highest in Nc/Nga mice. Consequently, we have chosen Nc/Nga mice as a model of AD/EV and tested efficacy of MVA and Dryvax vaccinations against a lethal intra-nasal (i.n.) challenge with WR, the surrogate of smallpox. Inoculation of MVA intra-muscularly (i.m.) or t.d. resulted in no lesions, while inoculation of Dryvax t.d. yielded large primary and many satellite lesions similar to WR. Eighty three and 92% of mice vaccinated with a single dose of MVA i.m. or t.d., respectively, survived a lethal i.n. challenge with WR without any serious illness, while all Dryvax-vaccinated animals survived. This is the first formal prove of protective immunity against a lethal poxvirus challenge induced by vaccination with MVA in an atopic organism.
Highlights
Vaccinia virus (VACV) from the Poxvirus family has been used as a live vaccine against smallpox
Highly attenuated vaccine based on nonreplicating Modified vaccinia virus Ankara (MVA; IMVAMUNE) is under clinical development and seems to induce good immune responses in blood tests and in animal models [3, 4, 5, 6, 7]
At the onset of experiments, we determined the conditions for development of atopic dermatitis in three different mouse strains: in spontaneously atopic Nc/Nga mice, in Th2-skewed Balb/c and in Th1-skewed C57Bl/6 mice
Summary
Vaccinia virus (VACV) from the Poxvirus family has been used as a live vaccine against smallpox. A worldwide vaccination campaign using various strains of VACV led to the eradication of this life-threatening disease. Highly attenuated vaccine based on nonreplicating Modified vaccinia virus Ankara (MVA; IMVAMUNE) is under clinical development and seems to induce good immune responses in blood tests and in animal models [3, 4, 5, 6, 7]. It is impossible, though, to test its efficacy in vivo in human
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.